ATTO - Attovia, an early-stage drug developer focused on immune-mediated diseases with high unmet need, is seeking to raise as much as $212.
ATTO - Attovia, an early-stage drug developer focused on immune-mediated diseases with high unmet need, is seeking to raise as much as $212.5M in a US IPO
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.